173 related articles for article (PubMed ID: 37932681)
21. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
22. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
23. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
[TBL] [Abstract][Full Text] [Related]
24. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N; Tahara M; Mizusawa J; Kodaira T; Fujii H; Yamazaki T; Mitani H; Iwae S; Fujimoto Y; Onozawa Y; Hanai N; Ogawa T; Hara H; Monden N; Shimura E; Minami S; Fujii T; Tanaka K; Homma A; Yoshimoto S; Oridate N; Omori K; Ueda T; Okami K; Ota I; Shiga K; Sugasawa M; Asakage T; Saito Y; Murono S; Nishimura Y; Nakamura K; Hayashi R;
J Clin Oncol; 2022 Jun; 40(18):1980-1990. PubMed ID: 35230884
[TBL] [Abstract][Full Text] [Related]
25. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
Fietkau R; Hecht M; Hofner B; Lubgan D; Iro H; Gefeller O; Rödel C; Hautmann MG; Kölbl O; Salay A; Rübe C; Melchior P; Breinl P; Krings W; Gripp S; Wollenberg B; Keerl R; Schreck U; Siekmeyer B; Grabenbauer GG; Balermpas P;
Radiother Oncol; 2020 Mar; 144():209-217. PubMed ID: 32044419
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
29. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer.
Tandon S; Gairola M; Ahlawat P; Rawat S; Aggarwal A; Sharma K; Tiwari S; Karimi AM; Muttagi V; Sachdeva N; Bhushan M
J Egypt Natl Canc Inst; 2018 Sep; 30(3):107-115. PubMed ID: 29960876
[TBL] [Abstract][Full Text] [Related]
31. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Cohen EE; Karrison TG; Kocherginsky M; Mueller J; Egan R; Huang CH; Brockstein BE; Agulnik MB; Mittal BB; Yunus F; Samant S; Raez LE; Mehra R; Kumar P; Ondrey F; Marchand P; Braegas B; Seiwert TY; Villaflor VM; Haraf DJ; Vokes EE
J Clin Oncol; 2014 Sep; 32(25):2735-43. PubMed ID: 25049329
[TBL] [Abstract][Full Text] [Related]
35. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J; Burtness B; Licitra LF; Nutting C; Schoenfeld JD; Omar M; Bouisset F; Nauwelaerts H; Urfer Y; Zanna C; Cohen EE
Future Oncol; 2022 May; 18(14):1669-1678. PubMed ID: 35172587
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
Terada M; Hara H; Daiko H; Mizusawa J; Kadota T; Hori K; Ogawa H; Ogata T; Sakanaka K; Sakamoto T; Kato K; Kitagawa Y
Jpn J Clin Oncol; 2019 Dec; 49(11):1055-1060. PubMed ID: 31411696
[TBL] [Abstract][Full Text] [Related]
37. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.
van den Bosch S; Dijkema T; Kunze-Busch MC; Terhaard CH; Raaijmakers CP; Doornaert PA; Hoebers FJ; Vergeer MR; Kreike B; Wijers OB; Oyen WJ; Kaanders JH
BMC Cancer; 2017 Mar; 17(1):208. PubMed ID: 28327089
[TBL] [Abstract][Full Text] [Related]
38. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
39. Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck.
Abdelhafiz N; Mahmoud D; Gad M; Essa H; Morsy A
J Med Life; 2023 May; 16(5):743-750. PubMed ID: 37520484
[TBL] [Abstract][Full Text] [Related]
40. Hyperbaric Oxygen as Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx: A Phase 1 Dose-Escalation Study.
Hartford AC; Davis TH; Buckey JC; Foote RL; Sinesi MS; Williams BB; Fariss AK; Schaner PE; Claus PL; Okuno SH; Hussey JR; Clarke RE
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):481-486. PubMed ID: 28126298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
